Dexpramipexole
As of the edition of 20 October 2026, Dexpramipexole is a small molecule: stopped in 2025; acts on DRD2, DRD3 and DRD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 21, 4 stopped early
- Disease areas
- Nervous system; Nutrition and metabolism; Blood and lymph; Lungs and airways; Immune system; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 8 | 6 | 1 | 0 |
| Phase 3 | 6 | 1 | 1 | 4 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Knopp Biosciences | Lead sponsor of trials | 2008 to now |
| Areteia Therapeutics | Lead sponsor of trials | 2023 to now |